ea0029p80 | Adrenal cortex | ICEECE2012
Germano A.
, Rapa I.
, De Francia S.
, Volante M.
, Laino F.
, Duregon E.
, Berruti A.
, Papotti M.
, Terzolo M.
Background: Mitotane (o,pDDD) is the reference therapy for adrenocortical carcinoma (ACC) and should undergo metabolization in o,pDDE and o,pDDA to exert its anti-proliferative activity. We have previously shown that there is a link between RRM1 gene expression and o,pDDD activity in an adjuvant setting. Aim of this study was to assess whether RRM1 gene expression is correlated to the bioavailability and cytotoxic activity of o,pDDD and its metabo...